Equities Analysts Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities researchers at Wedbush issued their Q1 2026 EPS estimates for shares of Day One Biopharmaceuticals in a research report issued on Wednesday, May 7th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.31) per share for the quarter. Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.33) EPS.

Several other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Finally, JPMorgan Chase & Co. dropped their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $6.45 on Thursday. The stock has a market cap of $653.73 million, a price-to-earnings ratio of -6.26 and a beta of -1.24. The business has a 50 day simple moving average of $7.70 and a 200 day simple moving average of $11.10. Day One Biopharmaceuticals has a 52-week low of $6.26 and a 52-week high of $17.14.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million during the quarter, compared to the consensus estimate of $30.28 million.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently bought and sold shares of DAWN. FMR LLC increased its position in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after buying an additional 5,475,087 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $31,829,000. Boxer Capital Management LLC bought a new stake in Day One Biopharmaceuticals in the 4th quarter valued at $15,077,000. Marshall Wace LLP acquired a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $13,909,000. Finally, Estuary Capital Management LP boosted its position in Day One Biopharmaceuticals by 35.5% during the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock worth $47,092,000 after purchasing an additional 972,997 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,064 shares of company stock valued at $251,925. Insiders own 6.20% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.